Search

Polypeptides Mimicking SP-C/SP-B Surfactant for RDS Treatment

The USPTO has granted Patent US12606609B2 to CHIESI FARMACEUTICI S.p.A. covering polypeptides that mimic the properties of human lung surfactant proteins SP-C and SP-B. The invention includes corresponding reconstituted surfactants and pharmaceutical compositions for treating or preventing neonatal respiratory distress syndrome (RDS) or acute RDS. The patent contains 30 claims and names Tore Curstedt and Jan Johansson as inventors.

Capsule Inhaler for PDE4 Inhibitor for Respiratory Treatment

USPTO published patent application US20260090986A1 for a capsule inhaler for administering a PDE4 inhibitor for respiratory treatment, filed by CHIESI FARMACEUTICI S.P.A. The application claims a dry powder inhalation device with a pharmaceutical composition comprising micronized particles of a PDE4 inhibitor and a carrier. This is an informational publication of a pending patent application with no regulatory implications.

Patent Application: Janus Kinase Inhibitors by Chiesi Farmaceutici

The USPTO has published a patent application (US20260085077A1) filed by Chiesi Farmaceutici S.P.A. The application describes compounds of general formula (I) that inhibit Janus Kinase (JAK) family kinases. These compounds are intended for therapeutic use in treating inflammatory diseases.

Capsule Inhaler for Phosphodiesterase-4 Inhibitor Patent Application

The USPTO has published a patent application (US20260083924A1) for a capsule inhaler device designed for administering a phosphodiesterase-4 inhibitor. The application, filed by Chiesi Farmaceutici S.P.A., details a drug product comprising a single-dose dry powder inhalation device and a pharmaceutical composition for treating respiratory diseases.

Capsule Inhaler Patent for Phosphodiesterase-4 Inhibitor

The USPTO has published a new patent application (US20260083711A1) for a capsule inhaler designed for administering phosphodiesterase-4 inhibitors. The patent, assigned to Chiesi Farmaceutici S.p.A., details a drug product comprising a single-dose dry powder inhalation device and a pharmaceutical composition for treating respiratory diseases.

CHMP Meeting Agenda Annex Lists 22 Products Under Review

EMA published the annex to the CHMP meeting agenda for 23-26 March 2026 (EMA/CHMP/49808/2026), covering 22 pharmaceutical products across annual reassessments, PSUR procedures, renewals, and variation type IB updates. Products under review include Lojuxta, Raxone, Defitelio, CARVYKTI, Fycompa, Tecvayli, Qdenga, RINVOQ, Kapruvia, Voxzogo, ALTUVOCT, Ezmekly, Lytgobi, Rozlytrek, Duvyzat, Aucatzyl, Fingolimod Mylan, Cometriq, Bylvay KAYFANDA, Imatinib Teva, Ranivisio Epruvy, Xarelto, Forxiga/Xigduo/Qtern/Edistride/Ebymect. This is a procedural working document; it does not create compliance obligations.